EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
Abstract
Authors
Martin Kaiser Attaya Suvannasankha Dawn Lee Ewa Dlotko Paul Macleod Natalie Boytsov Christina-Jane Crossman-Morgan Vinay Jadhav Gbenga Kazeem Connor Lloyd Molly Purser Justin Riemer Yevgeniy SAMYSHKIN Simon McNamara